We are upgrading the repository! A content freeze is in effect until December 11, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income
Authors
Wei, FeifeiMiglioretti, Diana L.
Connelly, Maureen T.
Andrade, Susan E.
Newton, Katherine M.
Hartsfield, Cynthia L.
Chan, K. Arnold
Buist, Diana S. M.
UMass Chan Affiliations
Meyers Primary Care InstituteDocument Type
Journal ArticlePublication Date
2005-11-17Keywords
AdultAged
Aged, 80 and over
Breast Neoplasms
Cardiovascular Diseases
Cohort Studies
Diabetes Mellitus
*Estrogen Replacement Therapy
Estrogens
Female
Humans
Middle Aged
Progesterone Congeners
Risk Factors
Health Services Research
Primary Care
Metadata
Show full item recordAbstract
BACKGROUND: We examined the impact of race, education, and household income on changes in rates of discontinuation and initiation of hormone therapy before and after release of the Women's Health Initiative estrogen plus progestin trial results. METHODS: We conducted an observational cohort study of 221 378 women aged 40-80 years enrolled in five health maintenance organizations to estimate the prevalence and rates of discontinuation and initiation of estrogen plus progestin and estrogen only between September 1, 1999, to June 31, 2002 (baseline), and December 31, 2002 (follow-up). We identified the census block group for each participant by geocoding her 2003 residential address. We categorized women into racial, education, and income groups based on the distribution of these characteristics in her community from year 2000 census data and the distributions of these characteristics within her HMO. RESULTS: There were significant differences in estrogen plus progestin and estrogen only prevalence by race, education level, and household income, and in estrogen plus progestin initiation by race and education level, but not by household income at follow-up. However, there were no differences by community race, education, or household income in change in the prevalence of either hormone therapy use at follow-up or in the rates of hormone therapy discontinuation or initiation from baseline to follow-up. CONCLUSIONS: Given the wide spread media attention to the Women's Health Initiative estrogen plus progestin trial results, our findings suggest comparable dissemination of this information across diverse socioeconomic groups.Source
J Natl Cancer Inst Monogr. 2005;(35):106-12. Link to article on publisher's siteDOI
10.1093/jncimonographs/lgi047Permanent Link to this Item
http://hdl.handle.net/20.500.14038/36972PubMed ID
16287895Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1093/jncimonographs/lgi047